OraSure Technologies (OSUR) : Shikiar Asset Management Inc reduced its stake in OraSure Technologies by 30.0% during the most recent quarter end. The investment management company now holds a total of 17,500 shares of OraSure Technologies which is valued at $127,575 after selling 7,500 shares in OraSure Technologies , the firm said in a disclosure report filed with the SEC on Apr 21, 2016.OraSure Technologies makes up approximately 0.06% of Shikiar Asset Management Inc’s portfolio.
OraSure Technologies closed down -0.13 points or -1.76% at $7.27 with 5,93,955 shares getting traded on Wednesday. Post opening the session at $7.4, the shares hit an intraday low of $7.11 and an intraday high of $7.53 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Other Hedge Funds, Including , First Quadrant L Pca boosted its stake in OSUR in the latest quarter, The investment management firm added 183,500 additional shares and now holds a total of 226,400 shares of OraSure Technologies which is valued at $1,650,456. OraSure Technologies makes up approx 0.04% of First Quadrant L Pca’s portfolio.Franklin Street Advisors Inc Nc reduced its stake in OSUR by selling 16,000 shares or 37.47% in the most recent quarter. The Hedge Fund company now holds 26,700 shares of OSUR which is valued at $189,837. OraSure Technologies makes up approx 0.04% of Franklin Street Advisors Inc Nc’s portfolio.Creative Planning reduced its stake in OSUR by selling 2,700 shares or 51.92% in the most recent quarter. The Hedge Fund company now holds 2,500 shares of OSUR which is valued at $17,550.
On the company’s financial health, OraSure Technologies reported $0.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Feb 3, 2016. Analyst had a consensus of $0.03. The company had revenue of $32.38 million for the quarter, compared to analysts expectations of $29.76 million. The company’s revenue was up 12.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.05 EPS.
OraSure Technologies Inc. (OraSure) is involved in the development manufacture marketing and sale of oral fluid diagnostic products and specimen collection devices and other diagnostic products designed to detect or diagnose critical medical conditions. These products include OraQuick In-Home HIV Test OraQuick ADVANCE OraSure HIV-1 oral specimen collection device OraQuick HCV rapid antibody test Intercept oral fluid drug testing system OraSure QuickFlu Rapid Flu A&B Test and Q.E.D. Saliva Alcohol test. The Company also manufactures and sells a range of cryosurgical products. Through its wholly owned subsidiary DNA Genotek Inc. the Company provides oral fluid sample collection stabilization and preparation products for molecular diagnostic applications.